1. Home
  2. PD vs DRUG Comparison

PD vs DRUG Comparison

Compare PD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$6.58

Market Cap

636.9M

Sector

Technology

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$87.10

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PD
DRUG
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.9M
707.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PD
DRUG
Price
$6.58
$87.10
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$12.63
$129.25
AVG Volume (30 Days)
2.5M
156.8K
Earning Date
05-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
416.95
N/A
EPS
1.87
N/A
Revenue
$492,546,000.00
N/A
Revenue This Year
$3.58
N/A
Revenue Next Year
$2.88
N/A
P/E Ratio
$3.61
N/A
Revenue Growth
5.36
N/A
52 Week Low
$5.70
$23.18
52 Week High
$17.45
$123.75

Technical Indicators

Market Signals
Indicator
PD
DRUG
Relative Strength Index (RSI) 49.66 59.14
Support Level $5.99 $72.06
Resistance Level $6.70 $91.69
Average True Range (ATR) 0.41 3.99
MACD 0.10 0.07
Stochastic Oscillator 61.11 63.17

Price Performance

Historical Comparison
PD
DRUG

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: